The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Safety profile of autologous macrophage therapy for liver cirrhosis
Open accessAbstract
Therapies to reduce liver fibrosis and stimulate organ regeneration are urgently needed. We conducted a first-in-human, phase 1 dose-escalation trial of autologous macrophage therapy in nine adults with cirrhosis and a Model for End-Stage Liver Disease (MELD) score of 10-16 (ISRCTN 10368050). Groups of three participants received a single peripheral infusion of 10 7, 10 8 or up to 10 9 cells. Leukapheresis and macrophage infusion were well tolerated with no transfusion reactions, dose-limiting toxicities or macrophage activation syndrome. All participants were alive and transplant-free at one year, with only one clinical event recorded, the occurrence of minimal ascites. The primary outcomes of safety and feasibility were met. This study informs and provides a rationale for efficacy studies in cirrhosis and other fibrotic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During 12 months of follow-up, 70 AEs were documented, with 44% considered related to the transplantation, but none of these AEs had a Common Terminology Criteria for Adverse Events (CTCAE) severity grading over 2.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in vitro expanded autologous BMDMs respectively through a peripheral vein [22].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“recent clinical trials have provided evidence that the administration of autologous macrophage therapy for liver fibrosis is safe, although the nature of these trials precluded efficacy assessment (52, 53).”
From Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis (2025) · cites this paper as [52]
The cited source says what the claim attributes to it.
In the citing paper
“Phase I studies demonstrated that macrophage infusion was safe and well-tolerated, and even showed improvement in some serum biomarkers after treatment (C3M, PRO-C3, and ELF) (176).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [176]
The cited source says what the claim attributes to it.
In the citing paper
“A reduction of MELD scores was observed in six of the nine patients 90 days following macrophage infusion, and in seven of the nine patients one year post-infusion.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the non-invasive measures of LC, such as serological markers of type-III collagen turnover, improved at day 90.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“A phase I trial (Moroni et al., 2019) first demonstrated that reinfusing autologous monocyte-derived macrophages (MDMs) into cirrhosis patients is safe and led to observed improvements in Model for End-Stage Liver Disease (MELD) score and liver stiffness (74).”
From Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics (2026) · cites this paper as [74]
In the citing paper
“The feasibility of the approach was further demonstrated by a Phase I clinical trial that injected autologous macrophages that express markers of tissue repair and inflammation resolution and showed an improvement in liver function and reduction of fibrosis markers (118).”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · cites this paper as [118]
In the citing paper
“In this proof-of-concept trial, apheresis-derived autologous CD14+ monocytes were differentiated ex vivo into a restorative phenotype (CD14+, high 25F9, CD206, CD163 and CD169). The single injection of different doses of these macrophages appeared safe and was associated with a (slight) reduction in the model of end-stage liver disease score.151”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [151]
In the citing paper
“The feasibility of such an approach was shown in a phase I clinical trial including nine patients with compensated cirrhosis.151”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [151]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., Ronco, C., Warnock, D. G., Levin, A., & the Acute Kidney Injury Network (2007) · Critical Care · doi:10.1186/cc5713 · Cited by 7,046
HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Henter, J., Horne, A., Aricò, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., Ladisch, S., McClain, K. L., Webb, D. K. H., Winiarski, J. H., et al. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.21039 · Cited by 5,396
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
D'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.013 · Cited by 2,687
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649
Self-citationDiagnosis of cirrhosis by transient elastography (FibroScan): a prospective study
Foucher, J. (2005) · Gut · doi:10.1136/gut.2005.069153 · Cited by 1,307
Ramachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001
Self-citationDose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Boulter, L., Govaere, O., Bird, T. G., Radulescu, S., Ramachandran, P., Pellicoro, A., Ridgway, R. A., Seo, S. S., Spee, B., Van Rooijen, N., et al. (2012) · Nature Medicine · doi:10.1038/nm.2667 · Cited by 747
Self-citationYounossi, Z. M., Guyatt, G. H., Kiwi, M. L., Boparai, N., & King, D. (1999) · Gut · doi:10.1136/gut.45.2.295 · Cited by 678
Cited by
Sorted by citations
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Wen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Alternatively activated macrophages promote resolution of necrosis following acute liver injury
Starkey Lewis, P., Campana, L., Aleksieva, N., Cartwright, J. A., Mackinnon, A., O'Duibhir, E., Kendall, T., Vermeren, M., Thomson, A., Gadd, V., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.031 · Cited by 209
Self-citationHepatic macrophages: Key players in the development and progression of liver fibrosis
Cheng, D., Chai, J., Wang, H., Fu, L., Peng, S., & Ni, X. (2021) · Liver International · doi:10.1111/liv.14940 · Cited by 188
Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy
Cai, X., Wang, J., Wang, J., Zhou, Q., Yang, B., He, Q., & Weng, Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104720 · Cited by 170
Liu, R., Li, X., Ma, H., Yang, Q., Shang, Q., Song, L., Zheng, Z., Zhang, S., Pan, Y., Huang, P., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.10.029 · Cited by 165
Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside
Rockey, D. C., & Friedman, S. L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.065 · Cited by 157
Cell therapy for advanced liver diseases: repair or rebuild
Dwyer, B. J., Macmillan, M. T., Brennan, P. N., & Forbes, S. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.014 · Cited by 141
Self-citationWatanabe, Y., Tsuchiya, A., & Terai, S. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0194 · Cited by 151
Future directions in acute liver failure
Stravitz, R. T., Fontana, R. J., Karvellas, C. J., Durkalski, V., McGuire, B. M., Rule, J. A., Tujios, S. R., Lee, W. M., & for the Acute Liver Failure Study Group (2023) · Hepatology · doi:10.1097/hep.0000000000000458 · Cited by 135
A new era of macrophage-based cell therapy
Na, Y. R., Kim, S. W., & Seok, S. H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01068-z · Cited by 129
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models
Dai, H., Zhu, C., Huai, Q., Xu, W., Zhu, J., Zhang, X., Zhang, X., Sun, B., Xu, H., Zheng, M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.034 · Cited by 114
Continuous human iPSC-macrophage production by suspension culture in stirred tank bioreactors
Ackermann, M., Hashtchin, A. R., Manstein, F., Oliveira, M. C., Kempf, H., Zweigerdt, R., & Lachmann, N. (2022) · Nature Protocols · doi:10.1038/s41596-021-00654-7 · Cited by 84
Macrophage in liver Fibrosis: Identities and mechanisms
Wang, Z., Du, K., Jin, N., Tang, B., & Zhang, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110357 · Cited by 119
Schwabe, R. F., & Brenner, D. A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01068-6 · Cited by 112
Qing, J., Ren, Y., Zhang, Y., Yan, M., Zhang, H., Wu, D., Ma, Y., Chen, Y., Huang, X., Wu, Q., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.032 · Cited by 107
Apoptotic cell identity induces distinct functional responses to IL-4 in efferocytic macrophages
Liebold, I., Al Jawazneh, A., Casar, C., Lanzloth, C., Leyk, S., Hamley, M., Wong, M. N., Kylies, D., Gräfe, S. K., Edenhofer, I., et al. (2024) · Science · doi:10.1126/science.abo7027 · Cited by 96
Feng, D., Xiang, X., Guan, Y., Guillot, A., Lu, H., Chang, C., He, Y., Wang, H., Pan, H., Ju, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166954 · Cited by 93
Takeuchi, S., Tsuchiya, A., Iwasawa, T., Nojiri, S., Watanabe, T., Ogawa, M., Yoshida, T., Fujiki, K., Koui, Y., Kido, T., et al. (2021) · npj Regenerative Medicine · doi:10.1038/s41536-021-00132-4 · Cited by 91
Macrophages: Subtypes, Distribution, Polarization, Immunomodulatory Functions, and Therapeutics
Peng, M., Li, N., Wang, H., Li, Y., Liu, H., Luo, Y., Lang, B., Zhang, W., Li, S., Tian, L., et al. (2025) · MedComm · doi:10.1002/mco2.70304 · Cited by 98
Collagen crosslinking: effect on structure, mechanics and fibrosis progression
Kong, W., Lyu, C., Liao, H., & Du, Y. (2021) · Biomedical Materials · doi:10.1088/1748-605x/ac2b79 · Cited by 89
Watanabe, T., Tsuchiya, A., Takeuchi, S., Nojiri, S., Yoshida, T., Ogawa, M., Itoh, M., Takamura, M., Suganami, T., Ogawa, Y., et al. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2020.03.012 · Cited by 87
Single-cell RNA sequencing reveals distinct immunology profiles in human keloid
Feng, C., Shan, M., Xia, Y., Zheng, Z., He, K., Wei, Y., Song, K., Meng, T., Liu, H., Hao, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940645 · Cited by 88
Gan, Z., Xiao, Z., Zhang, Z., Li, Y., Liu, C., Chen, X., Liu, Y., Wu, D., Liu, C., Shuai, X., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.01.011 · Cited by 84
Li, X., Huai, Q., Zhu, C., Zhang, X., Xu, W., Dai, H., & Wang, H. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.07.009 · Cited by 84
Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance
Roohani, S., & Tacke, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147249 · Cited by 79
Liu, J., Liu, J., Mu, W., Ma, Q., Zhai, X., Jin, B., Liu, Y., & Zhang, N. (2024) · ACS Nano · doi:10.1021/acsnano.4c02380 · Cited by 74
Macrophage reprogramming for therapy
Bart, V. M. T., Pickering, R. J., Taylor, P. R., & Ipseiz, N. (2020) · Immunology · doi:10.1111/imm.13300 · Cited by 73
How oxygenation shapes immune responses: emerging roles for physioxia and pathological hypoxia
Mirchandani, A. S., Sánchez-García, M. A., & Walmsley, S. R. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01087-5 · Cited by 77
Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial
Brennan, P. N., MacMillan, M., Manship, T., Moroni, F., Glover, A., Troland, D., MacPherson, I., Graham, C., Aird, R., Semple, S. I. K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03406-8 · Cited by 66
Self-citationWang, D., Chai, X.-Q., Hu, S.-S., & Pan, F. (2021) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2021.11.014 · Cited by 65
Human Induced Pluripotent Stem Cell-Derived Macrophages Ameliorate Liver Fibrosis
Pouyanfard, S., Meshgin, N., Cruz, L. S., Diggle, K., Hashemi, H., Pham, T. V., Fierro, M., Tamayo, P., Fanjul, A. N., Kisseleva, T., et al. (2021) · Stem Cells · doi:10.1002/stem.3449 · Cited by 60
Exosome-educated macrophages and exosomes differentially improve ligament healing
Chamberlain, C. S., Kink, J. A., Wildenauer, L. A., McCaughey, M., Henry, K., Spiker, A. M., Halanski, M. A., Hematti, P., & Vanderby, R. (2020) · Stem Cells · doi:10.1002/stem.3291 · Cited by 61
Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches
Conte, E. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108031 · Cited by 61
Macrophage immunotherapy: overcoming impediments to realize promise
Sly, L. M., & McKay, D. M. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.10.002 · Cited by 59
Engineering innate immune cells for cancer immunotherapy
Tarannum, M., Ding, X., Barisa, M., Hu, S., Anderson, J., Romee, R., & Zhang, J. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02629-5 · Cited by 64
Human iPSC-liver organoid transplantation reduces fibrosis through immunomodulation
Tadokoro, T., Murata, S., Kato, M., Ueno, Y., Tsuchida, T., Okumura, A., Kuse, Y., Konno, T., Uchida, Y., Yamakawa, Y., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg0338 · Cited by 58
Exploring Extracellular Matrix Crosslinking as a Therapeutic Approach to Fibrosis
Lloyd, S. M., & He, Y. (2024) · Cells · doi:10.3390/cells13050438 · Cited by 57
LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis
Klepfish, M., Gross, T., Vugman, M., Afratis, N. A., Havusha-Laufer, S., Brazowski, E., Solomonov, I., Varol, C., & Sagi, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00480 · Cited by 58
Lipoxin Mimetics and the Resolution of Inflammation
Godson, C., Guiry, P. J., & Brennan, E. P. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051921-085407 · Cited by 59
Treating inflammation to combat non-alcoholic fatty liver disease
Wiering, L., & Tacke, F. (2022) · Journal of Endocrinology · doi:10.1530/joe-22-0194 · Cited by 59
Киселева, В. В., Vishnyakova, P., Elchaninov, A. V., Fatkhudinov, T., & Sukhikh, G. T. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110583 · Cited by 55
Macrophages as key regulators of liver health and disease
Papachristoforou, E., & Ramachandran, P. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.006 · Cited by 56
Pharmacological Activation of Nrf2 Enhances Functional Liver Regeneration
Chan, B. K., Elmasry, M., Forootan, S. S., Russomanno, G., Bunday, T., Zhang, F., Brillant, N., Lewis, P. J. S., Aird, R. E., Ricci, E., et al. (2021) · Hepatology · doi:10.1002/hep.31859 · Cited by 52
Self-citationFibroblasts in liver cancer: functions and therapeutic translation
Affo, S., Filliol, A., Gores, G. J., & Schwabe, R. F. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00111-5 · Cited by 49
Targeting inflammation with chimeric antigen receptor macrophages using a signal switch
Cao, Q., Wang, Y., Chen, J., Wang, R., Chen, T., Gloss, B., Read, S. A., Wang, X., Lee, V. W. S., Clancy, L., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01387-8 · Cited by 50
“Ongoing clinical trials in various diseases are exploring the potential therapeutic application of ex vivo generated M2 macrophages 13,14 .”
A blueprint for translational regenerative medicine
Armstrong, J. P. K., Keane, T. J., Roques, A. C., Patrick, P. S., Mooney, C. M., Kuan, W., Pisupati, V., Oreffo, R. O. C., Stuckey, D. J., Watt, F. M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz2253 · Cited by 50
Self-citationXue, Y., Yan, X., Li, D., Dong, S., & Yuan, P. (2024) · Nature Communications · doi:10.1038/s41467-024-46210-1 · Cited by 54
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 52
Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting
Singanayagam, A., & Triantafyllou, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661182 · Cited by 47
The Gut–Liver Axis in Chronic Liver Disease: A Macrophage Perspective
Muynck, K. D., Vanderborght, B., Vlierberghe, H. V., & Devisscher, L. (2021) · Cells · doi:10.3390/cells10112959 · Cited by 48
Bartneck, M., Koppe, C., Fech, V., Warzecha, K. T., Kohlhepp, M., Huss, S., Weiskirchen, R., Trautwein, C., Luedde, T., & Tacke, F. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.08.012 · Cited by 44
Guillot, A., & Tacke, F. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000491 · Cited by 45
Duan, F., Guo, L., Yang, L., Han, Y., Thakur, A., Nilsson-Payant, B. E., Wang, P., Zhang, Z., Ma, C. Y., Zhou, X., et al. (2020) · doi:10.21203/rs.3.rs-62758/v1 · Cited by 44
Brennan, P., Macmillan, M. T., Manship, T. A., Moroni, F., Glover, A., Graham, C., Semple, S. I. K., Morris, D. M., Fraser, A. R., Pass, C., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-053190 · Cited by 41
Self-citationOrganoid transplant approaches for the liver
Reza, H. A., Okabe, R., & Takebe, T. (2021) · Transplant International · doi:10.1111/tri.14128 · Cited by 39
RNF41 orchestrates macrophage-driven fibrosis resolution and hepatic regeneration
Moreno-Lanceta, A., Medrano-Bosch, M., Fundora, Y., Perramón, M., Aspas, J., Parra-Robert, M., Baena, S., Fondevila, C., Edelman, E. R., Jiménez, W., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq6225 · Cited by 42
de Zawadzki, A., Leeming, D. J., Sanyal, A. J., Anstee, Q. M., Schattenberg, J. M., Friedman, S. L., Schuppan, D., & Karsdal, M. A. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.039 · Cited by 42
Self-citationMultifaceted Involvement of Microglia in Gray Matter Pathology in Multiple Sclerosis
Tsouki, F., & Williams, A. (2021) · Stem Cells · doi:10.1002/stem.3374 · Cited by 39
Duan, B., Liu, Y., Li, X., Han, M., Yu, H., Hong, H., Zhang, L., Xing, L., & Jiang, H. (2024) · Advanced Science · doi:10.1002/advs.202306899 · Cited by 38
Gurvich, O. L., Puttonen, K. A., Bailey, A., Kailaanmäki, A., Skirdenko, V., Sivonen, M., Pietikäinen, S., Parker, N. R., Ylä‐Herttuala, S., & Kekarainen, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-70967-2 · Cited by 40
Emerging synthetic drugs for the treatment of liver cirrhosis
Fallowfield, J. A., Ramos, M. J., & Robertson, A. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1918099 · Cited by 39
Self-citationResident Macrophages and Their Potential in Cardiac Tissue Engineering
Suku, M., Forrester, L. M., Biggs, M. J. P., & Monaghan, M. G. (2021) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2021.0036 · Cited by 41
Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils
Liang, Y., Xu, Q., & Gao, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291619 · Cited by 39
Macrophages derived from pluripotent stem cells: prospective applications and research gaps
Lyadova, I. V., & Vasiliev, A. V. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00824-4 · Cited by 38
The versatility of macrophage heterogeneity in liver fibrosis
Gao, C.-C., Bai, J., Han, H., & Qin, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968879 · Cited by 37
Harnessing metabolism of hepatic macrophages to aid liver regeneration
Liu, R., Scimeca, M., Sun, Q., Melino, G., Mauriello, A., Shao, C., Bernassola, F., Bove, P., Candi, E., Valentina, R., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06066-7 · Cited by 38
Lu, D., Jiao, X., Jiang, W., Yang, L., Gong, Q., Wang, X., Wei, M., & Gong, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115042 · Cited by 34
Cell therapy in end-stage liver disease: replace and remodel
Hu, X.-H., Chen, L., Wu, H., Tang, Y., Zheng, Q.-M., Wei, X., Wei, Q., Huang, Q., Chen, J., & Xu, X. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03370-z · Cited by 38
Therapeutic modulation of the liver immune microenvironment
Tilg, H., Adolph, T. E., & Tacke, F. (2023) · Hepatology · doi:10.1097/hep.0000000000000386 · Cited by 32
Emerging nanomedicines for macrophage-mediated cancer therapy
Shi, X., Rizvi, S. F. A., Yang, Y., & Liu, G. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.123028 · Cited by 32
Cell therapy for liver disorders: past, present and future
Ortuño‐Costela, M. D. C., Pinzani, M., & Vallier, L. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01050-2 · Cited by 34
Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice
Nojiri, S., Tsuchiya, A., Natsui, K., Takeuchi, S., Watanabe, T., Kojima, Y., Watanabe, Y., Kamimura, H., Ogawa, M., Motegi, S., et al. (2021) · Inflammation and Regeneration · doi:10.1186/s41232-021-00177-4 · Cited by 29
Shi, H., Wang, X., Sloas, C., Gerlach, B., Yurdagul, A., Moore, M. P., Jung, E. J., Mirshahi, F., Ronzoni, L., Sanyal, A. J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv2106 · Cited by 30
Yue, B., Gao, Y., Hu, Y., Zhan, M., Wu, Y., & Lu, L. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1731 · Cited by 26
Lipoxins and synthetic lipoxin mimetics: Therapeutic potential in renal diseases
Andrews, D. C., & Godson, C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158940 · Cited by 27
Wang, Y., Gong, X., Li, J., Wang, H., Xu, X., Wu, Y., Wang, J., Wang, S., Li, Y., & Zhang, Z. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01143-5 · Cited by 25
Isaacs‐Ten, A., Moreno‐Gonzalez, M., Bone, C., Märtens, A., Bernuzzi, F., Ludwig, T., Hellmich, C., Hiller, K., Rushworth, S. A., & Beraza, N. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.12.010 · Cited by 24
Cell transplantation-based regenerative medicine in liver diseases
Cardinale, V., Lanthier, N., Baptista, P. M., Carpino, G., Carnevale, G., Orlando, G., Angelico, R., Manzia, T. M., Schuppan, D., Pinzani, M., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.06.005 · Cited by 27
Key role of macrophages in the progression of hepatic fibrosis
Ran, J., Yin, S., Issa, R., Zhao, Q., Zhu, G., Zhang, H., Zhang, Q., Wu, C., & Li, J. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000602 · Cited by 25
From macrophage biology to macrophage-based cellular immunotherapies
Mass, E., & Lachmann, N. (2021) · Gene Therapy · doi:10.1038/s41434-021-00221-5 · Cited by 24
Forsberg, M. H., Kink, J. A., Thickens, A. S., Lewis, B. M., Childs, C. J., Hematti, P., & Capitini, C. M. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02491-7 · Cited by 24
Growth differentiation factor 15: Emerging role in liver diseases
Li, Y., Zhang, J., Chen, S., Ke, Y., Ke, Y., & Chen, Y. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156727 · Cited by 23
Taciak, B., Białasek, M., Kubiak, M., Marszałek, I., Górczak, M., Osadchuk, O., Kurpiel, D., Strzemecki, D., Barwik, K., Skorzynski, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56637-9 · Cited by 22
Targeting fibroblast activation protein with chimeric antigen receptor macrophages
Mao, Y., Chen, Y. M., Zhang, S., Zeng, Q., Wang, J., Sheng, C., & Chen, S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116604 · Cited by 23
Mesenchymal stem cells-based therapy in liver diseases
Han, H., Jin, W., & Li, X. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00088-x · Cited by 24
Regenerative medicine technologies applied to transplant medicine. An update
Petrosyan, A., Montali, F., Peloso, A., Citro, A., Byers, L. N., Pointe, C. L., Suleiman, M., Marchetti, A., McNeill, E. P., Speer, A. L., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1015628 · Cited by 22
Responses of hepatic sinusoidal cells to liver ischemia–reperfusion injury
Ito, Y., Hosono, K., & Amano, H. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1171317 · Cited by 22
Macrophages in the kidney in health, injury and repair
Bell, R. M. B., & Conway, B. R. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.01.005 · Cited by 23
Pistorius, K., Ly, L., Souza, P. R., Gómez, E. A., Koenis, D. S., Rodrı́guez, A. R., Foster, J., Sosabowski, J. K., Hopkinson, M., Rajeeve, V., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103974 · Cited by 20
Human liver immunology: from in vitro models to new insights
Rezvani, M. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01312-8 · Cited by 20
Recent advances in biomaterial-assisted cell therapy
Chen, Y., Pal, S., & Hu, Q. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00583b · Cited by 20
Li, B., Liu, J., Xin, X., Zhang, L., Zhou, J., Xia, C., Zhu, W., & Yu, H. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.51589 · Cited by 20
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
Geng, W., Liao, W., Cao, X., & Yang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13020393 · Cited by 20
Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study
Kronborg, T. M., Ytting, H., Hobolth, L., Møller, S., & Kimer, N. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.718896 · Cited by 18
Metadata
- Authors
- Moroni, F., Dwyer, B. J., Graham, C., Pass, C., Bailey, L., Ritchie, L., Mitchell, D., Glover, A., Laurie, A., Doig, S., Hargreaves, E., Fraser, A. R., Turner, M. L., Campbell, J. D. M., McGowan, N. W. A., Barry, J., Moore, J. K., Hayes, P. C., Leeming, D. J., Nielsen, M. J., Musa, K., Fallowfield, J. A., & Forbes, S. J.
- Affiliations
- MRC Centre for Regenerative Medicine (GB)
- University of Edinburgh (GB)
- Scottish National Blood Transfusion Service (GB)
- Guy's Hospital (GB)
- Centre for Inflammation Research (GB)
- Nordic Bioscience (Denmark) (DK)
- Corresponding author
- Forbes, Stuart J.
- ORCID
- Venue
- Nature Medicine
- Published
- 2019-10
- Volume
- 25
- Issue
- 10
- Pages
- 1560-1565
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2977548937
- Cited by
- 202
- References
- 35
- Citations by year
- 2026: 16 · 2025: 35 · 2024: 38 · 2023: 25 · 2022: 26 · 2021: 40 · 2020: 20 · 2019: 1
- FWCI
- 13.86
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- RCUK | Medical Research Council (MR/M007588/1)
- RCUK | MRC | Medical Research Foundation (MR/M007588/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- liver cirrhosis, liver fibrosis, leukapheresis, safety and tolerability, dose-limiting toxicity, macrophage activation syndrome, ascites
- MeSH terms
- Aged, Dose-Response Relationship, Immunologic, Female, Humans, Liver, Liver Cirrhosis, Liver Regeneration, Macrophages, Male, Middle Aged, End Stage Liver Disease, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
